Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.
about
Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlatesHigh serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND.Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.Oxidative stress: Biomarkers and novel therapeutic pathways.Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin.Managing anemia in patients with chronic heart failure: what do we know?Prognostic significance of erythropoietin in pancreatic adenocarcinomaThe role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questionsEffect of erythropoietin levels on mortality in old age: the Leiden 85-plus StudyThe cardiorenal syndrome: a reviewHeart failure-associated anemia: bone marrow dysfunction and response to erythropoietinAnemia and heart failure: a cause of progression or only a consequence?New avenues of exploration for erythropoietin.Frequent non-cardiac comorbidities in patients with chronic heart failure.Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.Anaemia and the heart.The role of erythropoietin in myocardial protection: potential mechanisms and applications.Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition StudyErythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors.Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitusTriple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.Erythropoietin: elucidating new cellular targets that broaden therapeutic strategiesMechanistic insights into diabetes mellitus and oxidative stressErythropoietin and oxidative stress.Etiology and management of anemia in patients with heart failure: how much iron is missing?Safety of intravitreally administered recombinant erythropoietin (an AOS thesis)G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction.Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling.Is there a role for erythropoietin in cardiovascular disease?Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis.Erythropoietin and the heart: facts and perspectives.Erythropoiesis-stimulating agents and heart failure.Anemia in heart failure: an overview of current concepts.Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms.Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.Anemia in chronic heart failure: can we treat? What to treat?Anemia and iron deficiency in heart failure.Pathophysiology of cardiorenal syndrome in patients with heart failure: Potential therapeutic targets.Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists?Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure.
P2860
Q28546759-F3656E77-E605-48B7-B7EE-1CAFB97A2020Q31037729-4274EC1C-358D-45C7-BA80-AEEA5E7E1B8BQ33433326-E708EFFC-C6A6-4270-805C-E5E0A77940F1Q33682262-A425518D-9863-45A1-8744-AD95DAB51B8DQ33750384-E5387192-49E5-429C-BB84-46433437D3CFQ33797640-E35EE927-30C3-4AAF-B523-D35676CE832EQ33988762-C63F5D1C-BAF7-4ADC-8E8F-64D80161AC4FQ34065957-8024A13F-227A-444D-AF48-6E86745223DBQ34403856-D533E8E6-CA2C-41DD-A366-BAE7AE1B9B70Q34495307-39CF8976-76F4-4630-A93D-D6DDAF1BABA5Q34663709-15855732-1E82-4E35-A4C1-0C2B0DDA2643Q35252704-A8A79DD7-F925-4AB1-A776-63FBE580E1BAQ35999785-4507F5AB-2E05-4497-8B59-657081E68935Q36046585-1142B2BE-0C3A-4885-A927-F766653EE85FQ36256384-F70A13EE-B814-445F-B966-81406411D99EQ36310888-ECAE6E24-7B66-4078-AB29-7F98BD2AC906Q36352011-47893DF2-F151-449B-9D80-A85C8B8378BBQ36423854-8889F0DD-8159-4E6B-B12D-414589D26787Q36555238-47EAC8FA-B4CA-4011-952E-B963A73A998EQ36663152-915C8015-37B7-4D1E-B2DB-5BD3682B33E4Q36727444-C577C47F-77BC-45D2-A198-267FFA508236Q36740470-A8BCFC03-0327-4822-B3F7-23016062F8D7Q36748171-72179EA8-BF9D-4857-A13E-2A2FE76E7D47Q36944477-DADADFB6-20DE-4B98-AC9D-591338DD98AFQ37078810-DA6EA9E5-9FF0-418D-9D4C-DF7696CDE067Q37106306-1A47AA82-1B7D-4C2A-9671-102FBBE8AFA7Q37176449-094F3F7C-D297-48BB-8607-B82889904818Q37182044-81416A03-4713-4B8C-AA19-636F0E969E32Q37661050-043E454B-FA9E-4006-A926-91C248312CCAQ37762930-B110EF37-7EEB-477D-818A-D192A0D1A043Q37798565-3A1E2D87-87B3-4E34-B390-5471D654EADAQ37802925-5CBD8C75-A5A7-426C-AB3E-DABCC8A76DE2Q37822727-2C0C618D-56C7-4AE4-B4CE-445C2A15BD24Q37845181-B238AB2A-6E06-4FA2-A219-0138ACA9DD67Q37883005-E0798E12-2EBE-4C2F-8153-5713EE008F85Q37943240-3B21AB7F-F122-44DA-932A-D940A20854C2Q38039849-79B92A61-0A86-42FB-A2C7-4A5C500D2BE6Q38667232-EF55D600-1EC1-4F16-8C6B-E6B4EC1791D5Q39660099-E944D5AC-7039-4326-9CE7-D8CE0B0DE35CQ40776947-FD554158-2EBD-41F8-B675-9B690A852DBF
P2860
Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Prognostic value of plasma ery ...... ts with chronic heart failure.
@en
Prognostic value of plasma ery ...... ts with chronic heart failure.
@nl
type
label
Prognostic value of plasma ery ...... ts with chronic heart failure.
@en
Prognostic value of plasma ery ...... ts with chronic heart failure.
@nl
prefLabel
Prognostic value of plasma ery ...... ts with chronic heart failure.
@en
Prognostic value of plasma ery ...... ts with chronic heart failure.
@nl
P2093
P921
P1476
Prognostic value of plasma ery ...... ts with chronic heart failure.
@en
P2093
Adriaan A Voors
Erik Lipsic
Peter van der Meer
Tom D J Smilde
P356
10.1016/J.JACC.2004.03.052
P407
P577
2004-07-01T00:00:00Z